India’s Big Eight Make Digital Leap With Two Acquisitions

Deals For AIOCD AWACS, Pharmarack

In an unprecedented move, eight of India’s top pharma companies, including Sun Pharma, Cipla, Torrent and Lupin, have set up a common vehicle for digitization initiatives. Having acquired local market research firm AIOCD AWACS and B2B platform Pharmarack, could the mandate extend to other services?

Two polygonal glowing hands, handshake, technology, business, trust concept
A Powerful Consortium Formed By India's Top Companies Aims For Digitization • Source: Shutterstock

In a landmark move, eight of the top Indian pharmaceutical companies have jointly set up a vehicle to drive digitization initiatives in the healthcare system. Two acquisitions were announced in as many days by their joint venture ABCD Technologies LLP, soon to be renamed IndoHealth Services LLP, but experts believe much more action is to follow.

The partners - Sun Pharmaceutical Industries Ltd., Cipla Limited, Torrent Pharmaceuticals Ltd., Lupin Limited, Dr....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from India

More from Focus On Asia

Glenmark Fortifying Branded Play, Shifts Focus To High Margin Products

 

Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.

China-Originated Assets Lead Global GLP-1 Deals

 
• By 

The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.

Zydus Looks To Ride gIbrance Exclusivity Wave; GLP-1 Battle-Ready With Differentiated Pen

 
• By 

Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.